Company / Net Income
Enliven Therapeutics, Inc. Net Income History
FY2019-FY2024 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Net Income
-$89.0M
FY2024
5-year range
-$89.0M / -$37.7M
FY2020-FY2024
Trend
-24.4%
vs FY2023
Sector context
#106 of 216
Health Care
What the data says
At -$89M, Enliven Therapeutics, Inc.'s net income ranks #106 of 216 in the Health Care sector. Declined from -$38M to -$89M over the past 2 years.
Based on SEC 10-K filings.
-$89M in FY2024.
Declined from -$38M to -$89M over the past 2 years.
Health Care sector context is included.
Net Income over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Sector benchmark
#106 of 216 in Health CareTop 49% of 216This company -$89.0M Sector average $454.1M
▼
-119.6% below sector average
Key checks
Key Insights
- In FY2024, net income decreased 24.4% year-over-year.
- Ranks #106 out of 216 companies in the Health Care sector.
- Peak net income was recorded in FY2019.
Company context
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- Altman Z-Score 7.84 (safe zone, above 2.9 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Net IncomeValue | YoY GrowthYoY |
|---|---|---|
| FY2024 | -$89.0M | -24.4% |
| FY2023 | -$71.6M | -90.1% |
| FY2022 | -$37.7M | +26.7% |
| FY2021 | -$51.4M | -24.2% |
| FY2020 | -$41.4M | -76.3% |
| FY2019 | -$23.5M | - |
As of FY2024 · SEC 10-K · Updated Feb 28, 2026